ESMO Releases Comments on Findings From the Pan-Cancer Atlas
The European Society for Medical Oncology (ESMO) welcomes the latest reports from The Cancer Genome Atlas (TCGA) as a major resource for researchers across the world and calls for increased across-the-board commitment to translate these efforts into medical advances for the benefit of patients with cancer. The genomic analysis, called the Pan-Cancer Atlas, is of more than 10,000 tumors from 33 types of cancer and has resulted in 29 published papers on the findings.
“The studies highlight genomic alterations in cancer tissue, but while it is tempting to believe that they are all important, sometimes giving a drug matched to the mutation does not benefit patients,” said Fabrice André, MD, PhD, Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Chair of the ESMO Translational Research and Personalised Medicine Working Group; Editor-in-Chief of ESMO’s flagship journal Annals of Oncology; and Co-Chair of the ESMO Molecular Analysis for Personalised Therapy (MAP) Congress. “Large-scale clinical trials are now needed to determine which alterations can be treated and are therefore relevant from a medical perspective,” he continued. “Cancer geneticists have done an incredible job identifying the mutations; now oncologists and the broader oncology community must take the lead and find out which mutations can be targeted to treat patients.”
Uniform Ranking System
Dr. André said that genomic alterations should now be ranked according to whether or not they can be treated. “This will avoid confusion between actionable alterations and alterations that are not medically relevant and therefore won’t translate into a benefit for patients. ESMO is currently devising a uniform ranking system that will help oncologists interpret data and explain the consequences to patients.”
The TCGA research confirms that some genomic alterations are shared across tumor types and suggests that cancer should be classified by these alterations, rather than the tissue of origin. For example, some mutational processes are shared across tumor types and could define subsets of patients eligible for targeted therapies or immunotherapy.
“In rare cancers that share genomic alterations, it may be time to seek pan-cancer registration for drugs,” said Dr. André. “But for some other cancers, it is too early to adopt this approach. We know that treating a certain mutation benefits patients with some types of cancer, but has no impact on other types of cancer. The TCGA project has been a massive investment that has shed light on cancer genomics. It is now time to translate these research findings into medical advances, and to achieve this, similar investment is needed in clinical research.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
